Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 20,612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Terminated Phase 2 Interventional Results available

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

NCT02259348
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions
Cyclophosphamide, Fludarabine, G-CSF, Interleukin-2, Melphalan, Thiotepa, Rituximab, Natural killer cell therapy, T-cell depleted HPC transplant, CD45RA-depleted HPC transplant
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

NCT02222155
View directory record Official record
Conditions
ANCA-associated Vasculitis
Interventions
CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 25, 2026, 9:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

NCT03198026
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Evaluating Spinal Cord Stimulation for Stiff Person Syndrome

NCT06242678
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
SCS trial lead
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 25, 2026, 9:37 PM EDT
Recruiting No phase listed Observational

Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens

NCT05171478
View directory record Official record
Conditions
Lung Cancer, Sarcoidosis
Interventions
Full-field optical coherence tomography
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 25, 2026, 9:37 PM EDT
Withdrawn Phase 1 Interventional

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

NCT06291415
View directory record Official record
Conditions
Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Interventions
HMPL-523
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma

NCT01716208
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ofatumumab + Fresh Frozen Plasma
Drug
Lead sponsor
Joseph Tuscano
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

NCT00648908
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Early Phase 1 Interventional Results available

Autonomic Neuropathy, GI Motility, and Inflammation in HIV

NCT02850276
View directory record Official record
Conditions
HIV Disease
Interventions
Pyridostigmine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 25, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

NCT00924040
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
BL22 (CAT-3888)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

NCT01309789
View directory record Official record
Conditions
Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell, Lymphoma, T-cell
Interventions
brentuximab vedotin, cyclophosphamide, prednisone, doxorubicin, vincristine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 25, 2026, 9:37 PM EDT
Withdrawn Phase 1 Interventional

Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression

NCT03047200
View directory record Official record
Conditions
Islet Cell Transplantation, Type 1 Diabetes
Interventions
Islet cell transplantation
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

NCT02753764
View directory record Official record
Conditions
Corticosteroid Resistant (CR) Asthmatics
Interventions
AZD7624, prednisone, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

NCT00003632
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, carmustine, cytarabine, etoposide, melphalan, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

POSSE Project: A Community-Level Intervention for Black YMSM

NCT03198663
View directory record Official record
Conditions
HIV/AIDS and Infections
Interventions
POSSE
Behavioral
Lead sponsor
Cook County Health
Government
Eligibility
15 Years to 25 Years · Male only
Enrollment
1,037 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 25, 2026, 9:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

NCT02294487
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care

NCT03670316
View directory record Official record
Conditions
HIV, AIDS, Smoking Cessation
Interventions
Algorithm Treatment, Quitline only
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 9:37 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions

NCT07605806
View directory record Official record
Conditions
Healthy Volunteer, Hypersensitivity Reactions, Vancomycin
Interventions
Vancomycin (IV)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 25, 2026, 9:37 PM EDT
Not listed Not applicable Interventional

The SEMS Project: Staying Employed With MS

NCT03647904
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
SEMS Project
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

NCT00472849
View directory record Official record
Conditions
Richter's Transformation, Leukemia
Interventions
Oxaliplatin, Fludarabine, Cytarabine, Rituximab, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Modulation Of Airway Reactivity With Chronic Mechanical Strain

NCT02396849
View directory record Official record
Conditions
Asthma
Interventions
Continuous Positive Airway Pressure (CPAP), Continuous Positive Airway Pressure (CPAP) Sham
Device
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Results available

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

NCT04157738
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes
Interventions
Rapid-Acting Insulin, Long acting insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
7 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

NCT00071448
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin human, insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 25, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 25, 2026, 9:37 PM EDT